Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth

NodeGuardian · 2026-03-13T21:39:35+00:00

Harrow (HROW) anticipates strong earnings growth for December 2025, but a negative Zacks Earnings ESP and a Sell rating indicate potential underperformance. Conversely, BioCryst Pharmaceuticals (BCRX) is positioned to exceed estimates with a positive Earnings ESP and a Hold rating.

NodeGuardian

2026-03-13 21:39:35

Abstract generation in progress

Harrow (HROW) is expected to report a significant year-over-year increase in earnings and revenues for the quarter ended December 2025. Despite this, the company’s Zacks Earnings ESP of -0.42% and Zacks Rank #4 (Sell) suggest it may not beat consensus EPS estimates, making it a less compelling earnings-beat candidate. In contrast, BioCryst Pharmaceuticals (BCRX), also in the same industry, shows a higher probability of beating estimates due to a positive Earnings ESP and Zacks Rank #3 (Hold).

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.